Gland Pharma Q1 net surges 47% to ₹317 cr on higher revenue
Growth driven by recent product launches from CDMO portfolio and strong customer demand. Investing in differentiated technologies and capacity expansions.
· 8/10/2026, 1:57:58 PM· 2 min read
Growth driven by recent product launches from CDMO portfolio and strong customer demand. Investing in differentiated technologies and capacity expansions.
Read original story →Related stories
business
Geopolitics drives valuation discipline for IPOs in H1-2026
business
RPSG Group’s Purvah Green to acquire 1.4 GWp solar plants from ReNew Solar for ₹4,859 crore
business
Stock markets end marginally higher on spike in crude oil prices
business